Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Cash from Operations (2016 - 2025)

International Stem Cell (ISCO) has disclosed Cash from Operations for 16 consecutive years, with 49000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 80.93% to 49000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 98000.0, a 139.52% decrease, with the full-year FY2024 number at 13000.0, down 98.6% from a year prior.
  • Cash from Operations was 49000.0 for Q3 2025 at International Stem Cell, up from 300000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 490000.0 in Q2 2023 to a low of 394000.0 in Q1 2021.
  • A 5-year average of 2473.68 and a median of 49000.0 in 2025 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: tumbled 1916.67% in 2021, then skyrocketed 1039.13% in 2023.
  • International Stem Cell's Cash from Operations stood at 316000.0 in 2021, then soared by 125.0% to 79000.0 in 2022, then surged by 103.8% to 161000.0 in 2023, then tumbled by 145.96% to 74000.0 in 2024, then skyrocketed by 166.22% to 49000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Cash from Operations are 49000.0 (Q3 2025), 300000.0 (Q2 2025), and 227000.0 (Q1 2025).